title: Effects of Hydroxydecine(®) (10-hydroxy-2-decenoic acid) on skin barrier structure and function in vitro and clinical efficacy in the treatment of UV-induced xerosis.
abstract: 10-Hydroxy-2-decenoic acid, a natural fatty acid only found in royal jelly, may be of value in correcting skin barrier dysfunction. We evaluated the activity of Hydroxydecine(®), its synthetic counterpart, in vitro on the regulation of epidermal differentiation markers, ex vivo on the inflammatory response and restoration of skin barrier function, and in vivo on UV-induced xerosis in healthy human volunteers. In cultured normal human keratinocytes, Hydroxydecine(®) induced involucrin, transglutaminase-1 and filaggrin protein production. In topically Hydroxydecine(®)-treated skin equivalents, immunohistochemical analysis revealed an increase in involucrin, transglutaminase-1 and filaggrin staining. In a model of thymic stromal lymphopoietin (TSLP)-induced inflamed epidermis, a Hydroxydecine(®)-containing emulsion inhibited TSLP release. In a model of inflammation and barrier impairment involving human skin explants maintained alive, Hydroxydecine(®) balm restored stratum corneum cohesion and significantly increased filaggrin expression, as shown by immunohistochemistry. It also decreased pro-inflammatory cytokine secretion (IL-4, IL-5 and IL-13). In healthy volunteers with UV-induced xerosis, the hydration index increased by +28.8% (p&#60;0.01) and +60.4% (p&#60;0.001) after 7 and 21 days of treatment with Hydroxydecine(®) cream, respectively. Hydroxydecine(®) thus proved its efficacy in activating keratinocyte differentiation processes in vitro, restoring skin barrier function and reducing inflammation ex vivo, and hydrating dry skin in vivo.
authors.affiliation: Centre R&D Pierre Fabre 3, avenue Hubert Curien, 31035 Toulouse, France. helene.duplan@pierre-fabre.com
authors.forename: Hélène
authors.initials: H
authors.lastname: Duplan
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Questel
authors.forename: Hélène
authors.initials: H
authors.lastname: Hernandez-Pigeon
authors.forename: Marie Florence
authors.initials: MF
authors.lastname: Galliano
authors.forename: Antony
authors.initials: A
authors.lastname: Caruana
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ceruti
authors.forename: Marco
authors.initials: M
authors.lastname: Ambonati
authors.forename: Carine
authors.initials: C
authors.lastname: Mejean
authors.forename: Odile
authors.initials: O
authors.lastname: Damour
authors.forename: Nathalie
authors.initials: N
authors.lastname: Castex-Rizzi
authors.forename: Sandrine
authors.initials: S
authors.lastname: Bessou-Touya
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Schmitt
mesh_terms: D001834:Body Water / Q000378:metabolism; D002454:Cell Differentiation; D004643:Emollients / Q000008:administration & dosage; D004817:Epidermis / Q000187:drug effects / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology* / Q000627:therapeutic use; D000091344:Filaggrin Proteins; D006801:Humans; D007150:Immunohistochemistry; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology; D012879:Skin Physiological Phenomena / Q000187:drug effects*; D014466:Ultraviolet Rays / Q000009:adverse effects
chemical_list: D004643:Emollients; C000717249:FLG protein, human; D005229:Fatty Acids, Monounsaturated; D000091344:Filaggrin Proteins; C055543:10-hydroxy-2-decenoic acid